Search results
Showing 851 to 900 of 8215 results
Recommendation ID NG228/06 Question Interventions for aneurysmal subarachnoid haemorrhage in people with major neurological deficit: What
Recommendation ID NG228/10 Question Intra-arterial therapies to manage delayed cerebral ischaemia: What is the impact of intra-arterial
Recommendation ID NG228/09 Question Intracranial hypertension: What is the impact of routine monitoring of intracranial hypertension on
Recommendation ID NG228/07 Question Managing acute hydrocephalus: What is the most clinically and cost-effective method of cerebrospinal
Recommendation ID NG37/02 Question Cystourethrogram: How accurate is the first CT scan with contrast (trauma scan) for detecting bladder
Recommendation ID NG228/03 Question Nimodipine: What is the clinical and cost effectiveness of nimodipine in the management of aneurysmal
Recommendation ID NG228/04 Question Novel endovascular interventions: What is the clinical and cost effectiveness of novel endovascular
Recommendation ID NG228/12 Question Blood pressure targets: What is the clinical and cost effectiveness of a lower blood pressure treatment
Recommendation ID NG228/13 Question Investigations for relatives: What is the clinical and cost effectiveness of investigations to detect
Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.
View recommendations for MTG75Show all sections
Our impact reports look at how the health and care system uses NICE's recommendations to improve people's health and care.
You can use our guidance and advice to find out what recommendations we have made about your condition or care needs. Our guidance goes beyond NHS...
Having a learning disability can affect how a person learns new things during their lifetime. They may need a range of extra support throughout life,...
Celebrating the people who support NICE: International Volunteer Day
Applauding the members of the public who donate their valuable experience and insight to NICE
NICE is unable to make a recommendation on cemiplimab (Libtayo) for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer in adults. This is because Sanofi did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA848
NICE is making changes to simplify our offer to the life sciences industry
A review of the impact our evidence-based guidance has on improvements in adult social care.
A review of the impact our evidence-based guidance has on improvements in lung cancer.
Find out more about the progress made in implementing NICE guidance on cardiovascular disease prevention
Find out about the progress made by the health and care system in implementing NICE guidance on end of life care for adults
Find out about the progress made by the health and care system in implementing NICE guidance on prostate cancer
Find out about the progress made by the health and care system in implementing NICE guidance on respiratory conditions
Find out about the progress made by the health and care system in implementing NICE guidance on children and young people's healthcare
Find out about the progress made by the health and care system in implementing NICE guidance on cardiovascular disease management
How NICE recommendations are being used to improve outcomes in priority areas of dementia care
Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) (TA846)
NICE is unable to make a recommendation on mepolizumab (Nucala) for treating severe hypereosinophilic syndrome in adults because GSK did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA846
NICE is unable to make a recommendation on mepolizumab (Nucala) for treating severe chronic rhinosinusitis with nasal polyps in adults because GSK did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA847
NICE is unable to make a recommendation on mepolizumab (Nucala) for treating eosinophilic granulomatosis with polyangiitis in people 6 years and over because GSK did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA845
Optilume for treating recurrent bulbar urethral strictures (MTG73)
Evidence-based recommendations on Optilume for treating recurrent bulbar urethral strictures.
View recommendations for MTG73Show all sections
GreenLight XPS for treating benign prostatic hyperplasia (MTG74)
Evidence-based recommendations on GreenLight XPS for benign prostatic hyperplasia.
View recommendations for MTG74Show all sections
Atrial fibrillation: DOACs and Vitamin K antagonists (IND247)
This indicator covers the percentage of patients with atrial fibrillation and a last recorded CHA2DS2-VASc score of 2 or more who are currently prescribed a direct-acting oral anticoagulant (DOAC) if eligible, or a vitamin K antagonist if not eligible for a DOAC or a DOAC is declined, clinically unsuitable or not indicated. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM231
Bipolar, schizophrenia and other psychoses: 6 physical health checks (IND248)
This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who, in the preceding 12 months, received all 6 elements of physical health checks for people with severe mental illness. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM232
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal) (TA843)
NICE is unable to make a recommendation on luspatercept (Reblozyl) for treating anaemia caused by beta-thalassaemia because BMS did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA843
Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal) (TA844)
NICE is unable to make a recommendation on luspatercept (Reblozyl) for treating anaemia caused by myelodysplastic syndromes because BMS did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA844
New life-extending treatment for rare forms of advanced gastroesophageal cancer recommended by NICE
Around 3,000 people could be eligible for a new life-extending combination therapy to treat rare forms of gastroesophageal cancer after NICE published final draft guidance today (24 November 2022).
This guideline covers assessing and managing pelvic fractures, open fractures and severe ankle fractures (known as pilon fractures and intra-articular distal tibia fractures) in pre-hospital settings (including ambulance services), emergency departments and major trauma centres. It aims to reduce deaths and long-term health problems by improving the quality of emergency and urgent care.
Tunnelled peritoneal drainage catheter insertion for refractory ascites in cirrhosis (IPG746)
Evidence-based recommendations on tunnelled peritoneal drainage catheter insertion for refractory ascites in cirrhosis. This involves inserting a catheter under the skin in the abdomen to drain excess fluid when needed, at home or in community care. The aim is to reduce the need for hospital admissions and improve quality of life.
View recommendations for IPG746Show all sections
Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management (NG228)
This guideline covers diagnosing and treating an aneurysmal (caused by a ruptured aneurysm) subarachnoid haemorrhage and its complications. It provides recommendations to improve diagnosis and ensure that the most effective treatments are offered. It includes guidance on follow-up care and information for people (aged 16 and over) who have had an aneurysmal subarachnoid haemorrhage, their families and carers.
NICE is unable to make a recommendation on carfilzomib (Kyprolis) with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma in adults. This is because Amgen did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA841
NICE is unable to make a recommendation on tisagenlecleucel (Kymriah) for treating relapsed or refractory follicular lymphoma in adults after 2 or more therapies. This is because Novartis did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA842
Register your organisation as a stakeholder with NICE.
Evidence-based recommendations on ab interno canaloplasty for open-angle glaucoma. This involves widening the channel that drains fluid from the eye. The aim is to reduce pressure in the eye.
View recommendations for IPG745Show all sections
NICE's impact on transition from children’s to adults’ services
NICE leads the way to develop a new approach to routinely value and pay for crucial antimicrobials
James Love-Koh talks about the next steps for the 3-year project to develop a routine framework for evaluating and paying for new antimicrobials.
NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over. This is because Novartis has confirmed that it does not intend to make an evidence submission for the appraisal. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA839
NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over. This is because Novartis has confirmed that it does not intend to make an evidence submission for the appraisal. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA840
June 2023: We are aware that the International Journal of Gynecology and Obstetrics have retracted a 2016 paper, which was used in committee decision making for this topic (IPG744). As the evidence base has now changed, it will be returning to committee for re-discussion. Once the schedule for this has been confirmed, it will be communicated to stakeholders and published on the NICE website. In the meantime, please refer to NICE's interventional procedures guidance on insertion of a balloon device to disimpact an engaged fetal head before an emergency caesarean section (IPG515) for guidance on this topic.
Three treatments for COVID have been recommended in draft NICE guidance released today for public consultation.
Targeted treatment for rare form of aggressive lung cancer gets NICE approval
Mobocertinib recommended as a treatment for a rare and aggressive form of lung cancer
Fetal balloon procedure is safe for delivering 'stuck' babies, NICE says
A balloon inflated underneath a baby’s head after they have become stuck in the pelvis during labour could be used to safely deliver them, NICE has said.